The FDA Just Went After 30 Companies Selling Knockoff Ozempic

Two companies stand out in the details. Kin Meds received a warning letter for plastering its website with claims like "Same Active Ingredient as common brands" and labeling products as compounded by Kin Meds when they actually weren't. That's textbook misbranding.

Then there's GenoGenix, which takes the cake for the most alarming violations. The company was accused of repackaging semaglutide, tirzepatide, and even retatrutide (a next-gen GLP-1 that isn't approved anywhere yet). Worse, GenoGenix was linked to unsanitary manufacturing conditions that resulted in three emergency room visits from contaminated products, including NAD+ vials loaded with excessive bacterial endotoxins. Not exactly the quality control you want in something you're injecting into your body.

Reasons to Be Concerned

The safety numbers tell a sobering story. As of spring 2025, the FDA had received over 520 adverse event reports tied to compounded semaglutide, and the real number is almost certainly higher because state-licensed pharmacies aren't required to report problems to the FDA.

Dosing errors have been a persistent nightmare. Some patients accidentally injected 5 to 20 times their intended dose because compounders gave instructions in "units" (a volume measurement that changes depending on concentration) instead of standard milligrams or milliliters. That's like a recipe calling for "a cup" without telling you whether it's a teacup or a Big Gulp. Reports of injectable products arriving warm or improperly cooled added another layer of concern, since temperature control matters enormously for these medications.

Big Pharma Is Playing Offense, Too

The FDA isn't the only one cracking down. Novo Nordisk (maker of Ozempic and Wegovy) has filed lawsuits against compounders and telehealth firms. Eli Lilly, which makes the competing tirzepatide drugs Mounjaro and Zepbound, has been equally aggressive with its own wave of litigation and cease-and-desist campaigns.

The most high-profile casualty so far: Hims & Hers, the telehealth giant, pulled its compounded GLP-1 pill from the market after the FDA's February 2026 enforcement announcement. That move came alongside a Novo Nordisk patent infringement lawsuit over a $49 Wegovy alternative and a referral to the Department of Justice for investigation. Not exactly a great week at the office.

Compounders aren't taking this lying down, though. In January 2026, Strive Compounding Pharmacy sued both Lilly and Novo in Texas federal court, alleging antitrust violations. The lawsuit claims the pharma giants used exclusive telehealth deals and product disparagement (calling compounded versions "unsafe" or "fake") to crush competition and keep prices high. Lilly called the suit "baseless deflection."

Where This Goes Next

FDA Commissioner Marty Makary has been blunt about the agency's intentions, stating he hopes 2026 will mark "the end of unlawful mass compounding of GLP-1s." The FDA plans to ramp up inspections of active ingredient manufacturers and tighten border restrictions on foreign-sourced ingredients, cutting off the supply chain that feeds many compounders.

Marta Wosińska, a senior fellow at the Brookings Institution's Center on Health Policy, offered a telling observation: the FDA now has significantly greater ability to use enforcement tools that effectively protect deals made with brand manufacturers. She also noted that the shift by Novo and Lilly toward pill formulations (rather than injectables) "makes a difference in terms of the ability to produce a lot of product quickly," potentially easing the supply constraints that created the compounding market in the first place.

The bigger picture here is a classic tension in healthcare. Branded GLP-1 drugs are extraordinarily expensive; U.S. spending on GLP-1s surged over 500% between 2018 and 2023 to reach $71.7 billion. Compounded versions were often dramatically cheaper, which is why millions of patients turned to them. Shutting down that market protects patients from genuinely dangerous products, but it also funnels everyone back toward drugs that many can't afford.

The FDA's 30 warning letters aren't the final chapter. They're the opening salvo of what Commissioner Makary clearly envisions as a full-scale cleanup. Companies have 15 working days to respond with corrective actions. For the compounders who don't comply, the next letter they receive probably won't be a warning. It'll be from a federal prosecutor.

Lonza Just Gave Back the Tech It Bought Eight Years Ago

Lonza sold its personalized medicine business back to the company that built it. Eight years after acquiring the Cocoon Platform from Octane Medical Group, the Swiss CDMO giant is handing back the keys, and the reasons say a lot about where biotech manufacturing is headed.